262 related articles for article (PubMed ID: 27589737)
21. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
[TBL] [Abstract][Full Text] [Related]
22. Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1.
Jin S; Ma H; Yang W; Ju H; Wang L; Zhang Z
J Mol Med (Berl); 2018 Jun; 96(6):513-525. PubMed ID: 29713760
[TBL] [Abstract][Full Text] [Related]
23. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.
Yu Y; Suryo Rahmanto Y; Richardson DR
Br J Pharmacol; 2012 Jan; 165(1):148-66. PubMed ID: 21658021
[TBL] [Abstract][Full Text] [Related]
24. Dp44mT, an iron chelator, suppresses growth and induces apoptosis via RORA-mediated NDRG2-IL6/JAK2/STAT3 signaling in glioma.
Zhou J; Jiang Y; Zhao J; Zhang H; Fu J; Luo P; Ma Y; Zou D; Gao H; Hu J; Zhang Y; Jing Z
Cell Oncol (Dordr); 2020 Jun; 43(3):461-475. PubMed ID: 32207044
[TBL] [Abstract][Full Text] [Related]
25. Operculina turpethum extract inhibits growth and proliferation by inhibiting NF-κB, COX-2 and cyclin D1 and induces apoptosis by up regulating P53 in oral cancer cells.
Arora R; Bharti V; Gaur P; Aggarwal S; Mittal M; Das SN
Arch Oral Biol; 2017 Aug; 80():1-9. PubMed ID: 28351666
[TBL] [Abstract][Full Text] [Related]
26. Daxx and TCF4 interaction links to oral squamous cell carcinoma growth by promoting cell cycle progression via induction of cyclin D1 expression.
Lin GJ; Huang YS; Lin CK; Huang SH; Shih HM; Sytwu HK; Chen YW
Clin Oral Investig; 2016 Apr; 20(3):533-40. PubMed ID: 26205068
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma.
Jia L; Wang J; Wu T; Wu J; Ling J; Cheng B
Mol Med Rep; 2017 Nov; 16(5):5779-5786. PubMed ID: 28849182
[TBL] [Abstract][Full Text] [Related]
28. NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization.
Sahni S; Gillson J; Park KC; Chiang S; Leck LYW; Jansson PJ; Richardson DR
Biochim Biophys Acta Gen Subj; 2020 Aug; 1864(8):129625. PubMed ID: 32335136
[TBL] [Abstract][Full Text] [Related]
29. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
Yuan J; Lovejoy DB; Richardson DR
Blood; 2004 Sep; 104(5):1450-8. PubMed ID: 15150082
[TBL] [Abstract][Full Text] [Related]
30. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.
Park KC; Geleta B; Leck LYW; Paluncic J; Chiang S; Jansson PJ; Kovacevic Z; Richardson DR
J Biol Chem; 2020 Jan; 295(2):481-503. PubMed ID: 31744884
[TBL] [Abstract][Full Text] [Related]
31. The Iron Chelator and Anticancer Agent Dp44mT Relieves Allergic Inflammation in Mice With Allergic Rhinitis.
Kim HY; Han NR; Kim HM; Jeong HJ
Inflammation; 2018 Oct; 41(5):1744-1754. PubMed ID: 29967928
[TBL] [Abstract][Full Text] [Related]
32. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
33. The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.
Wang J; Yin D; Xie C; Zheng T; Liang Y; Hong X; Lu Z; Song X; Song R; Yang H; Sun B; Bhatta N; Meng X; Pan S; Jiang H; Liu L
Oncotarget; 2014 Sep; 5(18):8478-91. PubMed ID: 25261367
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma.
Ge H; Liu H; Fu Z; Sun Z
J Int Med Res; 2012; 40(2):455-66. PubMed ID: 22613406
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Nagumo T; Takaoka S; Yoshiba S; Ohashi M; Shirota T; Hatori M; Isobe T; Tachikawa T; Shintani S
Oral Oncol; 2009 Sep; 45(9):766-70. PubMed ID: 19157955
[TBL] [Abstract][Full Text] [Related]
36. The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
Gundelach JH; Madhavan AA; Wettstein PJ; Bram RJ
FASEB J; 2013 Feb; 27(2):782-92. PubMed ID: 23134680
[TBL] [Abstract][Full Text] [Related]
37. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion.
Lui GY; Kovacevic Z; V Menezes S; Kalinowski DS; Merlot AM; Sahni S; Richardson DR
Mol Pharmacol; 2015; 87(3):543-60. PubMed ID: 25561562
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
[TBL] [Abstract][Full Text] [Related]
39. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Yasuda A; Kondo S; Nagumo T; Tsukamoto H; Mukudai Y; Umezawa K; Shintani S
Oral Oncol; 2011 May; 47(5):334-9. PubMed ID: 21459660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
